The Role of Antibody-dependent Enhancement in Dengue Vaccination

Overview

Journal Trop Dis Travel Med Vaccines

Publisher Biomed Central

Specialty Infectious Diseases

Date 2024 Nov 1

PMID 39482727

Authors

D G Aynekulu Mersha

I van der Sterren

L P M van Leeuwen

T Langerak

M S Hakim

B Martina

S F L van Lelyveld

E C M van Gorp

Affiliations

Soon will be listed here.

Abstract

Dengue is the most rapidly spreading vector-borne disease worldwide, with over half the global population at risk for an infection. Antibody-dependent enhancement (ADE) is associated with increased disease severity and may also be attributable to the deterioration of disease in vaccinated people. Two dengue vaccines are approved momentarily, with more in development. The increasing use of vaccines against dengue, combined with the development of more, makes a thorough understanding of the processes behind ADE more important than ever. Above that, due to the lack of treatment options, this method of prevention is of great importance. This review aims to explore the impact of ADE in dengue vaccinations, with the goal of enhancing potential vaccination strategies in the fight against dengue.

Citing Articles

Virus-Induced Pathogenic Antibodies: Lessons from Long COVID and Dengue Hemorrhage Fever.

Sun D, Lien T, Chang H Int J Mol Sci. 2025; 26(5).

PMID: 40076527 PMC: 11899886. DOI: 10.3390/ijms26051898.

Dengue Vaccination: A Practical Guide for Clinicians.

See K Vaccines (Basel). 2025; 13(2).

PMID: 40006692 PMC: 11861165. DOI: 10.3390/vaccines13020145.

Utility of VIDAS Dengue Diagnostic Assays to Differentiate Primary and Secondary Dengue Infection: A Cross-Sectional Study in a Military Hospital from Colombia.

Prieto-Torres A, Medina-Lozano L, Ramirez-Avila J, Faccini-Martinez A Trop Med Infect Dis. 2025; 10(2).

PMID: 39998044 PMC: 11860576. DOI: 10.3390/tropicalmed10020040.

References

Lenharo M . Dengue is breaking records in the Americas - what's behind the surge?. Nature. 2023; . DOI: 10.1038/d41586-023-02423-w. View

Zust R, Li S, Xie X, Velumani S, Chng M, Toh Y . Characterization of a candidate tetravalent vaccine based on 2'-O-methyltransferase mutants. PLoS One. 2018; 13(1):e0189262. PMC: 5751980. DOI: 10.1371/journal.pone.0189262. View

Halstead S, Russell P, Brandt W . NS1, Dengue's Dagger. J Infect Dis. 2019; 221(6):857-860. DOI: 10.1093/infdis/jiz083. View

Ubol S, Phuklia W, Kalayanarooj S, Modhiran N . Mechanisms of immune evasion induced by a complex of dengue virus and preexisting enhancing antibodies. J Infect Dis. 2010; 201(6):923-35. DOI: 10.1086/651018. View

Hadinegoro S, Arredondo-Garcia J, Capeding M, Deseda C, Chotpitayasunondh T, Dietze R . Efficacy and Long-Term Safety of a Dengue Vaccine in Regions of Endemic Disease. N Engl J Med. 2015; 373(13):1195-206. DOI: 10.1056/NEJMoa1506223. View

Zatta M, Brichler S, Vindrios W, Melica G, Gallien S . Autochthonous Dengue Outbreak, Paris Region, France, September-October 2023. Emerg Infect Dis. 2023; 29(12):2538-2540. PMC: 10683815. DOI: 10.3201/eid2912.231472. View

Fernandez E, Dejnirattisai W, Cao B, Scheaffer S, Supasa P, Wongwiwat W . Human antibodies to the dengue virus E-dimer epitope have therapeutic activity against Zika virus infection. Nat Immunol. 2017; 18(11):1261-1269. PMC: 5679314. DOI: 10.1038/ni.3849. View

Monsalvo A, Batalle J, Lopez M, Krause J, Klemenc J, Hernandez J . Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes. Nat Med. 2010; 17(2):195-9. PMC: 3034774. DOI: 10.1038/nm.2262. View

Rolph M, Zaid A, Rulli N, Mahalingam S . Downregulation of interferon-β in antibody-dependent enhancement of dengue viral infections of human macrophages is dependent on interleukin-6. J Infect Dis. 2011; 204(3):489-91. DOI: 10.1093/infdis/jir271. View

10.

COBRA C, Rigau-Perez J, Kuno G, Vorndam V . Symptoms of dengue fever in relation to host immunologic response and virus serotype, Puerto Rico, 1990-1991. Am J Epidemiol. 1995; 142(11):1204-11. DOI: 10.1093/oxfordjournals.aje.a117579. View

11.

. Dengue vaccine: WHO position paper, September 2018 - Recommendations. Vaccine. 2018; 37(35):4848-4849. DOI: 10.1016/j.vaccine.2018.09.063. View

12.

Mamo T, Poland G . Nanovaccinology: the next generation of vaccines meets 21st century materials science and engineering. Vaccine. 2012; 30(47):6609-11. DOI: 10.1016/j.vaccine.2012.08.023. View

13.

Rivera L, Biswal S, Saez-Llorens X, Reynales H, Lopez-Medina E, Borja-Tabora C . Three-year Efficacy and Safety of Takeda's Dengue Vaccine Candidate (TAK-003). Clin Infect Dis. 2021; 75(1):107-117. PMC: 9402653. DOI: 10.1093/cid/ciab864. View

14.

Wilder-Smith A, Hombach J, Ferguson N, Selgelid M, OBrien K, Vannice K . Deliberations of the Strategic Advisory Group of Experts on Immunization on the use of CYD-TDV dengue vaccine. Lancet Infect Dis. 2018; 19(1):e31-e38. DOI: 10.1016/S1473-3099(18)30494-8. View

15.

Guzman M, Alvarez M, Halstead S . Secondary infection as a risk factor for dengue hemorrhagic fever/dengue shock syndrome: an historical perspective and role of antibody-dependent enhancement of infection. Arch Virol. 2013; 158(7):1445-59. DOI: 10.1007/s00705-013-1645-3. View

16.

Biswal S, Reynales H, Saez-Llorens X, Lopez P, Borja-Tabora C, Kosalaraksa P . Efficacy of a Tetravalent Dengue Vaccine in Healthy Children and Adolescents. N Engl J Med. 2019; 381(21):2009-2019. DOI: 10.1056/NEJMoa1903869. View

17.

Halstead S, Mahalingam S, Marovich M, Ubol S, Mosser D . Intrinsic antibody-dependent enhancement of microbial infection in macrophages: disease regulation by immune complexes. Lancet Infect Dis. 2010; 10(10):712-22. PMC: 3057165. DOI: 10.1016/S1473-3099(10)70166-3. View

18.

Delatte H, Gimonneau G, Triboire A, Fontenille D . Influence of temperature on immature development, survival, longevity, fecundity, and gonotrophic cycles of Aedes albopictus, vector of chikungunya and dengue in the Indian Ocean. J Med Entomol. 2009; 46(1):33-41. DOI: 10.1603/033.046.0105. View

19.

Watts D, Burke D, Harrison B, Whitmire R, Nisalak A . Effect of temperature on the vector efficiency of Aedes aegypti for dengue 2 virus. Am J Trop Med Hyg. 1987; 36(1):143-52. DOI: 10.4269/ajtmh.1987.36.143. View

20.

Rueda L, Patel K, Axtell R, Stinner R . Temperature-dependent development and survival rates of Culex quinquefasciatus and Aedes aegypti (Diptera: Culicidae). J Med Entomol. 1990; 27(5):892-8. DOI: 10.1093/jmedent/27.5.892. View